UNIGE document Scientific Article
previous document  unige:27155  next document
add to browser collection
Title

Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection

Authors
Söderholm, Jonas
Waldenström, Jesper
Askarieh, Galia
Pilli, Massimo
Pawlotsky, Jean-Michel
Zeuzem, Stefan
show hidden authors show all authors [1 - 18]
Published in PLOS ONE. 2013, vol. 8, no. 2, p. e56991
Abstract Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50-80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.
Identifiers
PMID: 23437290
Full text
Article (Published version) (363 Kb) - public document Free access
Structures
Research group Etudes et traitement de l'hépatite C et B (554)
Citation
(ISO format)
SÖDERHOLM, Jonas et al. Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. In: PLOS ONE, 2013, vol. 8, n° 2, p. e56991. https://archive-ouverte.unige.ch/unige:27155

193 hits

20 downloads

Update

Deposited on : 2013-04-03

Export document
Format :
Citation style :